2024
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
1982
Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S, Kirkwood J, Mitchell M, Nordlund J, Lerner A, Papac R. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery 1982, 92: 459-63. PMID: 7112396.Peer-Reviewed Original ResearchConceptsBacillus Calmette-GuerinSurgical adjuvant immunotherapyMER-BCGAdjuvant immunotherapyControl groupHigh-risk malignant melanomaDisease-free survivalHigh-risk melanomaIntraoperative infiltrationImmunotherapy groupIntradermal vaccinationIntralymphatic immunotherapyRegional lymphadenectomyConsecutive patientsSurgical excisionCalmette-GuerinMalignant melanomaPatientsImmunotherapyMethanol-extractable residueLymphadenectomyRecurrenceMelanomaExtremitiesSame interval